Skip to main content
Hangzhou Tigermed Consulting Co.,Ltd. logo

Hangzhou Tigermed Consulting Co.,Ltd. — Investor Relations & Filings

Ticker · 300347 ISIN · CNE100001KV8 LEI · 300300CP4N8WDF6DOO67 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,288 across all filing types
Latest filing 2026-05-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300347

About Hangzhou Tigermed Consulting Co.,Ltd.

https://www.tigermedgrp.com

Hangzhou Tigermed Consulting Co.,Ltd. provides comprehensive clinical research solutions for the pharmaceutical, biotechnology, and medical device sectors. The company offers a full suite of services across the drug development lifecycle, including clinical trial management from Phase I to IV, regulatory affairs, data management, biostatistics, medical writing, and pharmacovigilance. Its capabilities extend to specialized areas such as central laboratory services, site management, and medical imaging. Tigermed focuses on accelerating the development and commercialization of innovative therapies by leveraging an extensive clinical network and technical expertise to navigate complex regulatory requirements. The integrated service model is designed to optimize trial efficiency and maintain high standards of data quality and compliance for global clinical development programs.

Recent filings

Filing Released Lang Actions
关于取得金融机构股票回购贷款承诺函的公告
Capital/Financing Update Classification · 85% confidence The document is an official announcement by the company concerning obtaining a bank loan commitment specifically to finance a share repurchase plan. It details the loan amount, term, and purpose (stock buyback), which qualifies as a financing activity update rather than the repurchase execution itself. Therefore, it falls under Capital/Financing Update (CAP).
2026-05-26 Chinese
关于召开2026年第二次临时股东会、2026年第二次A股类别股东会议及2026年第二次H股类别股东会议的公告
Proxy Solicitation & Information Statement Classification · 89% confidence The document is a detailed notice convening the 2026 second extraordinary general meeting (temporarily called shareholders’ meeting), including meeting date, time, location, agenda items (proposals on share repurchase), voting methods, registration procedures, and proxy forms (attachments). It is not the meeting minutes or voting results, but rather the solicitation of proxies and informational statement for shareholders to prepare and vote. This matches the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-19 Chinese
关于回购公司部分股份事项前十名A股股东和前十名无限售条件A股股东持股情况的公告
Transaction in Own Shares Classification · 85% confidence The document is an official announcement by Hangzhou Tigermed regarding its board-approved share repurchase plan and details the shareholding of the top ten A-share holders and top ten unrestricted A-share holders prior to the repurchase resolution. This falls under the category of a company’s transaction in its own shares (share buyback) rather than a capital raising or general regulatory filing. Therefore, it should be classified as a Transaction in Own Shares (Code: POS).
2026-05-19 Chinese
关于持股5%以上股东部分股份回购并解除质押的公告
Major Shareholding Notification Classification · 78% confidence The document is an announcement by the company regarding a >5% shareholder’s partial share repurchase and release of pledged shares. It details the pledge changes but does not involve the company buying back its own stock, is not a dividend, financing, M&A, management change, etc. This type of disclosure falls under changes in significant shareholding/pledge status by a major shareholder, which maps to Major Shareholding Notification (MRQ).
2026-05-14 Chinese
第五届董事会第二十五次会议决议公告
Transaction in Own Shares Classification · 78% confidence The document is a board of directors meeting resolution announcement outlining the company’s plan to repurchase its own A-share stock, including the amount, price range, sources of funds, and authorization details. This is not a management change notice or merely a publication announcement, but a share buyback plan resolution. According to the taxonomy, reports on share repurchases fall under “Transaction in Own Shares” (POS).
2026-05-13 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 85% confidence The document is a ‘简式权益变动报告书’ (Simplified Report of Shareholding Changes) filed by the controlling shareholders (“信息披露义务人”) of the company. It details cumulative changes in their equity stake (including passive dilution and active trades) which trigger a mandatory disclosure when the holding moves past statutory thresholds. This is not an internal management change, earnings release, or an announcement of an attached report, but a detailed notification of major shareholding changes. Therefore, it best fits the Major Shareholding Notification category.
2026-05-12 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.